Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study

• Published in: Journal of thoracic disease Vol. 12; no. 5; pp. 1811 - 1823
• Main Authors: Wu, Fan, Zhou, Yumin, Wang, Zhongfang, Xie, Min, Shi, Zhe, Tang, Zhiqiang, Li, Xiaohe, Li, Xiaochen, Lei, Chunliang, Li, Yimin, Ni, Zhengyi, Hu, Yu, Liu, Xiaoqing, Yin, Wenguang, Cheng, Linling, Ye, Feng, Peng, Jieqi, Huang, Lingmei, Tian, Jia, Zhang, Lingjuan, Mo, Xiaoneng, Zhang, Ying, Hu, Ke, Jiang, Yongliang, Guan, Weijie, Xiang, Jie, Liu, Yingxia, Peng, Yixiang, Wei, Li, Hu, Yahua, Peng, Peng, Wang, Jianming, Liu, Jiyang, Huang, Wei, Chen, Ruchong, Zhao, Jianping, Li, Shiyue, Zhang, Nuofu, Zhao, Jincun, Zhong, Nanshan, Ran, Pixin
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.05.2020
• Subjects: Original; Clinical characteristics; chronic obstructive pulmonary disease (COPD); coronavirus disease 2019 (COVID-19)
• ISSN: 2072-1439; 2077-6624
• DOI: 10.21037/jtd-20-1914

Coronavirus disease 2019 (COVID-19) has been a global pandemic disease, with more than 4 million cases and nearly 300,000 deaths. Little is known about COVID-19 in patients with chronic obstructive pulmonary disease (COPD). We aimed to evaluate the influence of preexisting COPD on the progress and outcomes of COVID-19. This was a multicenter, retrospective, observational study. We enrolled 1,048 patients aged 40 years and above, including 50 patients with COPD and 998 patients without COPD, and with COVID-19 confirmed via high-throughput sequencing or real-time reverse transcription-polymerase chain reaction, between December 11, 2019 and February 20, 2020. We collected data of demographics, pathologic test results, radiologic imaging, and treatments. The primary outcomes were composite endpoints determined by admission to an intensive care unit, the use of mechanical ventilation, or death. Compared with patients who had COVID-19 but not COPD, those with COPD had higher rates of fatigue (56.0% 40.2%), dyspnea (66.0% 26.3%), diarrhea (16.0% 3.6%), and unconsciousness (8.0% 1.7%) and a significantly higher proportion of increased activated partial thromboplastin time (23.5% 5.2%) and D-dimer (65.9% 29.3%), as well as ground-glass opacities (77.6% 60.3%), local patchy shadowing (61.2% 41.4%), and interstitial abnormalities (51.0% 19.8%) on chest computed tomography. Patients with COPD were more likely to develop bacterial or fungal coinfection (20.0% 5.9%), acute respiratory distress syndrome (ARDS) (20.0% 7.3%), septic shock (14.0% 2.3%), or acute renal failure (12.0% 1.3%). Patients with COPD and COVID-19 had a higher risk of reaching the composite endpoints [hazard ratio (HR): 2.17, 95% confidence interval (CI): 1.40-3.38; P=0.001] or death (HR: 2.28, 95% CI: 1.15-4.51; P=0.019), after adjustment. In this study, patients with COPD who developed COVID-19 showed a higher risk of admission to the intensive care unit, mechanical ventilation, or death.